TENAYA and LUCERNE
University of Nevada, Reno · Sierra Eye Associates · +22 more institutions
Abstract
PurposeTo evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A.DesignTENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) were identically designed, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials.ParticipantsTreatment-naive patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older.MethodsPatients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) or aflibercept 2.0 mg every 8 weeks (Q8W). Faricimab fixed dosing based on protocol-defined disease activity at weeks 20 and 24 up…
Citation impact
- FWCI
- 77.91
- Percentile
- 100%
- References
- 29
Authors
317- AMArshad M. KhananiCorresponding
University of Nevada, Reno, Sierra Eye Associates
- AKAachal Kotecha
Roche (United Kingdom)
- ACAndrew Chang
The University of Sydney, Sydney Hospital, UNSW Sydney
- SCShih‐Jen Chen
National Yang Ming Chiao Tung University, Taipei Veterans General Hospital
- YCYouxin Chen
Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital
Topics & keywords
- Medicine
- Zero hunger